In:
Cellular Therapy and Transplantation, Foundation for the Development of Bone Marrow Transplantation, Vol. 9, No. 2 ( 2020-7-30), p. 67-70
Abstract:
Blinatumomab, a bispecific T-cell engaging CD3-CD19 antibody, is highly effective in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) even after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, patients who failed with Blina have a dismal outcome. Inotuzumab ozogamicin is one of the therapeutic options after blinatumomab failure. We report a young man who exhibited bone marrow (BM) relapse of B-ALL following haploidentical stem cell transplantation (haplo-HSCT). Remission was not achieved after Blinotumomab treatment, thus Inotuzumab was administered. A complete remission with no signs of minimal residual disease was achieved after a single cycle of Inotuzumab. The second haplo-HSCT from another donor was successful.
Conclusion The present case demonstrate an opportunity of successful inotuzumab therapy after failure of allo-HSCT and blinotumomab treatment.
Type of Medium:
Online Resource
ISSN:
1866-8836
Uniform Title:
Успешное применение инотузумаба озогамицина при лечении резистентного В-клеточного острого лимфобластного лейкоза, рефрактерного к блинотумомабу
DOI:
10.18620/ctt-1866-8836-2020-9-2
DOI:
10.18620/ctt-1866-8836
DOI:
10.18620/ctt-1866-8836-2020-9-2-67-70
Language:
English
Publisher:
Foundation for the Development of Bone Marrow Transplantation
Publication Date:
2020
detail.hit.zdb_id:
2442744-5
Permalink